Athersys is a biotechnology business based in the US. Athersys shares (ATHX) are listed on the NASDAQ and all prices are listed in US Dollars. Athersys employs 24 staff and has a trailing 12-month revenue of around $146,000.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $0.33 |
|---|---|
| 52-week range | $0.26 - $2.76 |
| 50-day moving average | $0.50 |
| 200-day moving average | $0.95 |
| Wall St. target price | $5.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.67 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.33 from 2023-09-27
| 1 week (2023-09-21) | 17.86% |
|---|---|
| 1 month (2023-08-28) | -28.26% |
| 3 months (2023-06-28) | -57.69% |
| 6 months (2023-03-28) | -74.02% |
| 1 year (2022-09-28) | -79.75% |
|---|---|
| 2 years (2021-09-28) | -76.26% |
| 3 years (2020-09-28) | 2.08 |
| 5 years (2018-09-28) | 2.1 |
| Revenue TTM | $146,000 |
|---|---|
| Gross profit TTM | $-65,566,000 |
| Return on assets TTM | -104.09% |
| Return on equity TTM | -1276.02% |
| Profit margin | 0% |
| Book value | $-1.71 |
| Market Capitalization | $8.9 million |
TTM: trailing 12 months
We're not expecting Athersys to pay a dividend over the next 12 months.
Athersys's shares were split on a 1:25 basis on 28 August 2022. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Athersys shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Athersys shares which in turn could have impacted Athersys's share price.
Over the last 12 months, Athersys's shares have ranged in value from as little as $0.256 up to $2.76. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Athersys's is -0.7358. This would suggest that Athersys's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Athersys has bucked the trend.
Athersys, Inc. , a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K. K.
Everything we know about the Discord IPO, plus information on how to buy in.
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.
Steps to owning and managing HGGG, with 24-hour and historical pricing before you buy.